[go: up one dir, main page]

HN2006015130A - Asociacion entre la ferroquina y un derivado de artemisina para el tratamiento del paludismo - Google Patents

Asociacion entre la ferroquina y un derivado de artemisina para el tratamiento del paludismo

Info

Publication number
HN2006015130A
HN2006015130A HN2006015130A HN2006015130A HN2006015130A HN 2006015130 A HN2006015130 A HN 2006015130A HN 2006015130 A HN2006015130 A HN 2006015130A HN 2006015130 A HN2006015130 A HN 2006015130A HN 2006015130 A HN2006015130 A HN 2006015130A
Authority
HN
Honduras
Prior art keywords
treatment
association
paludism
artemisine
railway
Prior art date
Application number
HN2006015130A
Other languages
English (en)
Inventor
Fraisse Laurent
Ter-Minassian Daniel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HN2006015130A publication Critical patent/HN2006015130A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una nueva asociacion, util para el tratamiento y/o la prevencion del paludismo.
HN2006015130A 2005-04-20 2006-04-20 Asociacion entre la ferroquina y un derivado de artemisina para el tratamiento del paludismo HN2006015130A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503932A FR2884715B1 (fr) 2005-04-20 2005-04-20 Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme

Publications (1)

Publication Number Publication Date
HN2006015130A true HN2006015130A (es) 2010-08-19

Family

ID=35385843

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2006015130A HN2006015130A (es) 2005-04-20 2006-04-20 Asociacion entre la ferroquina y un derivado de artemisina para el tratamiento del paludismo

Country Status (30)

Country Link
US (1) US20120258945A1 (es)
EP (1) EP1874293A1 (es)
JP (1) JP5148478B2 (es)
KR (1) KR20080009088A (es)
CN (2) CN102836163A (es)
AP (1) AP2782A (es)
AR (1) AR054253A1 (es)
AU (1) AU2006238506B2 (es)
BR (1) BRPI0610851A2 (es)
CA (1) CA2605385A1 (es)
CR (1) CR9425A (es)
DO (1) DOP2006000092A (es)
EA (1) EA012630B1 (es)
FR (1) FR2884715B1 (es)
GT (1) GT200600157A (es)
HN (1) HN2006015130A (es)
IL (1) IL186048A0 (es)
MA (1) MA29451B1 (es)
MX (1) MX2007012645A (es)
MY (1) MY145581A (es)
NO (1) NO20075920L (es)
NZ (1) NZ562117A (es)
PA (1) PA8669801A1 (es)
PE (2) PE20061314A1 (es)
SG (1) SG161270A1 (es)
TN (1) TNSN07359A1 (es)
TW (1) TWI387456B (es)
UA (1) UA96414C2 (es)
WO (1) WO2006111647A1 (es)
ZA (1) ZA200708800B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926993B1 (fr) * 2008-02-06 2011-03-11 Sanofi Aventis Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artemisinine ou l'un de ses derives pour le traitement du paludisme
FR2952823B1 (fr) * 2009-10-30 2012-04-20 Sanofi Aventis Utilisation de la ferroquine dans le traitement ou la prevention du paludisme
FR2951945B1 (fr) * 2009-11-05 2013-08-09 Sanofi Aventis Composition pharmaceutique
FR2961209B1 (fr) * 2010-06-11 2013-03-01 Sanofi Aventis Procede de synthese de la ferroquine par amination reductrice convergente.
FR2989588A1 (fr) * 2012-04-19 2013-10-25 Centre Nat Rech Scient Composes pour la prevention ou le traitement des infections par des virus de la famille des flaviviridae
MX382486B (es) 2013-11-08 2025-03-13 Exthera Medical Corp Métodos para diagnosticar enfermedades infecciosas usando medio de adsorción.
CN105250295B (zh) * 2014-07-07 2018-12-25 广州中医药大学科技产业园有限公司 一种联合用药物及其作为免疫调节剂的应用
US10512652B2 (en) 2015-07-20 2019-12-24 University Of Vermont And State Agricultural College Use of cymanquine compounds as antimalarial agents
CN107802755A (zh) * 2017-11-08 2018-03-16 江西龙卿堂科技有限公司 一种具有防蚊防疟作用的青蒿软膏
KR102073961B1 (ko) * 2018-11-16 2020-02-05 (주)프론트바이오 메트포르민 및 페로센계 화합물을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
BR112022026791A2 (pt) * 2020-07-09 2023-05-02 Ceva Sante Animale Composições veterinárias para prevenção e/ou tratamento de leishmaniose
TW202220645A (zh) * 2020-08-14 2022-06-01 印度商太陽製藥工業有限公司 用於治療瘧疾的固定劑量組合藥物
WO2022231238A1 (ko) * 2021-04-26 2022-11-03 심민보 아르테수네이트 또는 그의 염, 및 피로나리딘 또는 그의 염의 해열, 항염증, 항바이러스용, 또는 covid-19 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
CN113952360B (zh) * 2021-09-14 2023-03-10 上海交通大学 一种亚铁离子在治疗疟疾的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN166154B (es) * 1987-05-08 1990-03-24 Hoechst India
BRPI0413767A (pt) * 2003-09-04 2006-10-31 Cipla Ltd produto farmacêutico ou formulação farmacêutica, processo para preparar um produto farmacêutico ou formulação farmacêutica, método para tratar um doença e uso de pelo menos uma artemisinina ou um sal, solvato ou derivado desta

Also Published As

Publication number Publication date
AU2006238506A1 (en) 2006-10-26
CN101163470A (zh) 2008-04-16
ZA200708800B (en) 2009-01-28
CN102836163A (zh) 2012-12-26
JP2008536900A (ja) 2008-09-11
CR9425A (es) 2008-02-20
AU2006238506B2 (en) 2012-03-01
AP2782A (en) 2013-10-31
WO2006111647A1 (fr) 2006-10-26
TW200716092A (en) 2007-05-01
DOP2006000092A (es) 2006-11-15
EP1874293A1 (fr) 2008-01-09
EA012630B1 (ru) 2009-10-30
MX2007012645A (es) 2007-12-13
MA29451B1 (fr) 2008-05-02
SG161270A1 (en) 2010-05-27
PE20061314A1 (es) 2006-12-27
BRPI0610851A2 (pt) 2010-08-03
JP5148478B2 (ja) 2013-02-20
PE20110119A1 (es) 2011-03-08
US20120258945A1 (en) 2012-10-11
IL186048A0 (en) 2008-02-09
NO20075920L (no) 2007-11-16
KR20080009088A (ko) 2008-01-24
FR2884715B1 (fr) 2007-06-15
NZ562117A (en) 2010-01-29
AP2007004211A0 (en) 2007-10-31
EA200702282A1 (ru) 2008-02-28
GT200600157A (es) 2006-11-07
UA96414C2 (ru) 2011-11-10
TWI387456B (zh) 2013-03-01
CA2605385A1 (fr) 2006-10-26
TNSN07359A1 (en) 2008-12-31
FR2884715A1 (fr) 2006-10-27
MY145581A (en) 2012-02-29
PA8669801A1 (es) 2006-11-09
AR054253A1 (es) 2007-06-13

Similar Documents

Publication Publication Date Title
CR11292A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
HN2006015130A (es) Asociacion entre la ferroquina y un derivado de artemisina para el tratamiento del paludismo
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
HN2006000668A (es) Compuestos de quinolina heteroaromaticos
HN2006018410A (es) Nuevos derivados del fluoreno, composiciones que los contienen y utilizacion
CU20080044A7 (es) Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
CR20110103A (es) Heteroarilos sustituidos
CR7970S (es) Botella
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
ECSP12011585A (es) Compuestos y composiciones para eltratamiento de enfermedades parasitarias
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
ECSP10010409A (es) INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
NO20082298L (no) Kaliumkanalinhibitorer
CR20110202A (es) Antagonistas de la via hedgehog de ftalazina disustituida
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
MX2009012767A (es) Metodos de tratamiento de infecciones fungicas.
PA8667201A1 (es) Nuevos compuestos farmaceuticos
UA97401C2 (ru) Экструдат с улучшенной маскировкой вкуса
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
DE502006005053D1 (de) Spritzbare akustikmassen
CR20120558A (es) Terapia de combinación que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinético